UnknownPhase 2NCT05396937

Efficacy and Safety of T+A+RAD in HCC

Studying Combined hepatocellular carcinoma and cholangiocarcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Fudan University
Principal Investigator
Lu Wang
Fudan University
Intervention
Multifocal Stereotactic Radiotherapy(radiation)
Enrollment
42 enrolled
Eligibility
18-70 years · All sexes
Timeline
20222023

Study locations (1)

Collaborators

Roche Pharma AG

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05396937 on ClinicalTrials.gov

Other trials for Combined hepatocellular carcinoma and cholangiocarcinoma

Additional recruiting or active studies for the same condition.

See all trials for Combined hepatocellular carcinoma and cholangiocarcinoma

← Back to all trials